Arthritis

2
Pipeline Programs
6
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
tanezumab 10 mgPhase 32 trials
MethotrexateN/A1 trial
Active Trials
NCT01414257Completed2,860Est. Mar 2014
NCT00994890Terminated679Est. Mar 2011
NCT00830063Completed832Est. Aug 2010
UP
UCB PharmaBelgium - Brussels
1 program
1
CDP6038Phase 1/21 trial
Active Trials
NCT01009242Completed40Est. Sep 2010
Medacta
MedactaSwitzerland - Castel San Pietro
3 programs
GMK Sphere Knee ReplacementN/A1 trial
GMK Sphere cementless Knee ReplacementN/A1 trial
Hydrogel coatingN/A1 trial
Active Trials
NCT02199600Active Not RecruitingEst. Oct 2029
NCT05003414Active Not RecruitingEst. Dec 2032
NCT05679232RecruitingEst. Dec 2027
Precision BioSciences
1 program
Custom Fabricated SplintN/A1 trial
Active Trials
NCT05351060Unknown10Est. Aug 2022
Alliance Pharmaceuticals
1 program
Total hip replacementN/A1 trial
Active Trials
NCT00738803Unknown100Est. Apr 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Pfizertanezumab 10 mg
Pfizertanezumab 10 mg
UCB PharmaCDP6038
MedactaHydrogel coating
Precision BioSciencesCustom Fabricated Splint
MedactaGMK Sphere cementless Knee Replacement
MedactaGMK Sphere Knee Replacement
PfizerMethotrexate
Alliance PharmaceuticalsTotal hip replacement

Clinical Trials (9)

Total enrollment: 4,521 patients across 9 trials

NCT00830063Pfizertanezumab 10 mg

Tanezumab In Osteoarthritis Of The Knee (2)

Start: May 2009Est. completion: Aug 2010832 patients
Phase 3Completed
NCT00994890Pfizertanezumab 10 mg

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

Start: Nov 2009Est. completion: Mar 2011679 patients
Phase 2Terminated
NCT01009242UCB PharmaCDP6038

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

Start: Oct 2009Est. completion: Sep 201040 patients
Phase 1/2Completed
NCT05679232MedactaHydrogel coating

Hydrogel Coating to Reduce Post-surgical Infection After Joint Arthroplasty

Start: Dec 2022Est. completion: Dec 2027
N/ARecruiting
NCT05351060Precision BioSciencesCustom Fabricated Splint

Novel Splinting Technique Using 3D Models

Start: May 2022Est. completion: Aug 202210 patients
N/AUnknown
NCT05003414MedactaGMK Sphere cementless Knee Replacement

The Medacta International GMK Sphere Cementless Post-Marketing Surveillance Study

Start: Jan 2020Est. completion: Dec 2032
N/AActive Not Recruiting
NCT02199600MedactaGMK Sphere Knee Replacement

The Medacta International GMK Sphere Post-Marketing Surveillance Study

Start: Oct 2012Est. completion: Oct 2029
N/AActive Not Recruiting
NCT01414257PfizerMethotrexate

Methotrexate (Rheumatrex) High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)

Start: May 2011Est. completion: Mar 20142,860 patients
N/ACompleted
NCT00738803Alliance PharmaceuticalsTotal hip replacement

Restoration of Leg Length, Offset, and Center of Rotation in Total Hip Replacement

Start: Jun 2007Est. completion: Apr 2010100 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 4,521 patients
6 companies competing in this space